European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor ...
RAHWAY, N.J.--(BUSINESS WIRE)--Jun 24, 2026-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev ® (enfortumab vedotin-ejfv), an …